These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 7946003)
1. A risk-benefit assessment of drugs used in the management of Parkinson's disease. Bodagh IY; Robertson DR Drug Saf; 1994 Aug; 11(2):94-103. PubMed ID: 7946003 [TBL] [Abstract][Full Text] [Related]
3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
4. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Kurth MC Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854 [TBL] [Abstract][Full Text] [Related]
10. Levodopa in the early treatment of Parkinson's disease. Murata M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036 [TBL] [Abstract][Full Text] [Related]
11. Medical treatment of Parkinson's disease. Ahlskog JE Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977 [No Abstract] [Full Text] [Related]
12. Parkinson's disease: initial treatment of motor disorders. Prescrire Int; 2015 Sep; 24(163):215-7. PubMed ID: 26417634 [TBL] [Abstract][Full Text] [Related]
13. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in the treatment of Parkinson's disease. Martocci RJ J Am Osteopath Assoc; 1975 Apr; 74(8):730-41. PubMed ID: 1092751 [No Abstract] [Full Text] [Related]
15. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073 [TBL] [Abstract][Full Text] [Related]
16. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. Jankovic J; Stacy M CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819 [TBL] [Abstract][Full Text] [Related]
17. Safinamide for the treatment of Parkinson's disease. Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164 [TBL] [Abstract][Full Text] [Related]
18. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]